Roivant Sciences reported a first-quarter GAAP loss of $0.26 per share, beating analyst estimates by $0.06, while revenue of $1.44 million fell short of expectations by $0.9 million and declined 33.6% year-over-year. General and administrative expenses rose to $165.5 million from $134.0 million a year earlier, driven largely by a $26.1 million increase in personnel-related costs that included $18.8 million in employee bonuses tied to a global settlement with Moderna in March 2026. Non-GAAP G&A expenses were $90.7 million, up from $62.6 million in the same quarter last year.
Roivant Sciences LtdQ1 revenue fell short and declined 33.6% YoY, while G&A expenses rose, despite EPS beat.
Moderna Inc